BRPI1015569A2 - compostos úteis para o tratamento de doenças degenerativas e inflamatórias. - Google Patents

compostos úteis para o tratamento de doenças degenerativas e inflamatórias.

Info

Publication number
BRPI1015569A2
BRPI1015569A2 BRPI1015569A BRPI1015569A BRPI1015569A2 BR PI1015569 A2 BRPI1015569 A2 BR PI1015569A2 BR PI1015569 A BRPI1015569 A BR PI1015569A BR PI1015569 A BRPI1015569 A BR PI1015569A BR PI1015569 A2 BRPI1015569 A2 BR PI1015569A2
Authority
BR
Brazil
Prior art keywords
degenerative
treatment
inflammatory diseases
compounds useful
compounds
Prior art date
Application number
BRPI1015569A
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Koen Kurt Smits
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015569(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BRPI1015569A2 publication Critical patent/BRPI1015569A2/pt
Publication of BRPI1015569B1 publication Critical patent/BRPI1015569B1/pt
Publication of BRPI1015569B8 publication Critical patent/BRPI1015569B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015569A 2009-06-26 2010-06-25 compostos úteis para o tratamento de doenças degenerativas e inflamatórias BRPI1015569B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068809P 2009-06-26 2009-06-26
US61/220,688 2009-06-26
PCT/EP2010/059064 WO2010149769A1 (en) 2009-06-26 2010-06-25 5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Publications (3)

Publication Number Publication Date
BRPI1015569A2 true BRPI1015569A2 (pt) 2016-08-16
BRPI1015569B1 BRPI1015569B1 (pt) 2020-10-27
BRPI1015569B8 BRPI1015569B8 (pt) 2021-05-25

Family

ID=42562363

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015569A BRPI1015569B8 (pt) 2009-06-26 2010-06-25 compostos úteis para o tratamento de doenças degenerativas e inflamatórias

Country Status (43)

Country Link
US (9) US8088764B2 (pt)
EP (2) EP2445911B1 (pt)
JP (2) JP5591925B2 (pt)
KR (3) KR101850716B1 (pt)
CN (2) CN102482273B (pt)
AR (1) AR077220A1 (pt)
AU (3) AU2010264633B2 (pt)
BR (1) BRPI1015569B8 (pt)
CA (1) CA2765985C (pt)
CL (1) CL2011003247A1 (pt)
CO (1) CO6491040A2 (pt)
CR (1) CR20120016A (pt)
CY (3) CY1119214T1 (pt)
DK (2) DK3178819T3 (pt)
DO (1) DOP2011000388A (pt)
EA (1) EA021637B1 (pt)
EC (1) ECSP12011626A (pt)
ES (2) ES2766573T3 (pt)
FR (1) FR21C1011I2 (pt)
GB (1) GB2483424B (pt)
HR (2) HRP20170826T1 (pt)
HU (3) HUE047478T2 (pt)
IL (1) IL216667A (pt)
LT (3) LT2445911T (pt)
MA (1) MA33448B1 (pt)
ME (1) ME02699B (pt)
MX (1) MX344951B (pt)
MY (1) MY156664A (pt)
NI (1) NI201100222A (pt)
NL (1) NL301096I2 (pt)
NO (1) NO2021013I1 (pt)
NZ (1) NZ596838A (pt)
PE (1) PE20121032A1 (pt)
PL (2) PL3178819T3 (pt)
PT (2) PT2445911T (pt)
RS (1) RS56035B1 (pt)
SG (2) SG177363A1 (pt)
SI (2) SI3178819T1 (pt)
SM (1) SMT201700265T1 (pt)
TW (1) TWI462920B (pt)
UA (1) UA107935C2 (pt)
WO (1) WO2010149769A1 (pt)
ZA (1) ZA201109386B (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
EP2770992A4 (en) * 2011-10-26 2015-12-30 Emily A Stein AGENTS, METHODS AND DEVICES FOR AFFECTING NERVOUS FUNCTION
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
HUE038878T2 (hu) 2012-06-22 2018-12-28 Galapagos Nv Aminotriazolopirimidin gyulladás kezelésében történõ alkalmazásra és gyógyászati készítményeik
GB201302036D0 (en) * 2013-02-05 2013-03-20 Queen Mary & Westfield College Diagnosis
WO2015089153A1 (en) * 2013-12-11 2015-06-18 Cephalon, Inc. Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP2018511620A (ja) 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法
RS64677B1 (sr) * 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017133423A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
MX2018011422A (es) * 2016-03-21 2019-07-08 Crystal Pharmatech Co Ltd Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
WO2018019223A1 (zh) * 2016-07-26 2018-02-01 张文燕 作为选择性jak抑制剂化合物，该化合物的盐类及其治疗用途
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
WO2018087202A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202400019T1 (it) 2017-03-14 2024-03-13 Galapagos Nv Composizioni farmaceutiche comprendenti un inibitore jak
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
CN111154711B (zh) * 2018-11-07 2022-08-05 杭州瑞普晨创科技有限公司 JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
KR102737181B1 (ko) 2019-03-14 2024-12-02 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. Jak 억제제 및 그 제조방법과 의약분야에서의 응용
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN113677676A (zh) * 2019-03-30 2021-11-19 联合化学实验室有限公司 一种制备非戈替尼及其中间体的新方法
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
CN110204542B (zh) * 2019-05-23 2022-05-20 四川伊诺达博医药科技有限公司 一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) * 2019-06-03 2019-08-23 上海基科生物化学有限公司 一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
IT201900020240A1 (it) 2019-11-04 2021-05-04 Advitech Advisory And Tech Sa Procedimento per la preparazione di Filgotinib e intermedi di sintesi
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN110878097B (zh) * 2019-11-29 2021-11-02 杭州科巢生物科技有限公司 菲格替尼的制备方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12419873B2 (en) 2020-02-13 2025-09-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
AU2021222686B2 (en) 2020-02-21 2023-06-29 Zhuhai United Laboratories Co., Ltd. Crystalline form of JAK inhibitor and application thereof
WO2022039850A1 (en) * 2020-08-17 2022-02-24 Vyne Therapeutics Inc. Tofacitinib-containing anhydrous elastomer-based gel formulations
US20230355608A1 (en) * 2020-10-02 2023-11-09 University Of Massachusetts Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) * 2021-05-19 2022-11-22 奥锐特药业(天津)有限公司 一种Filgotinib中间体的制备方法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2026027669A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib
WO2026027676A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208996A (en) 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
ATE283840T1 (de) 1999-01-29 2004-12-15 Chugai Pharmaceutical Co Ltd Chondrogonese promotoren und indolin-2-on derivate
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2006517580A (ja) 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
EP2178868A1 (en) 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100035875A1 (en) 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
KR20110033223A (ko) 2008-06-20 2011-03-30 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
NZ597140A (en) 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
HUE038878T2 (hu) 2012-06-22 2018-12-28 Galapagos Nv Aminotriazolopirimidin gyulladás kezelésében történõ alkalmazásra és gyógyászati készítményeik
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
RS64677B1 (sr) 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja

Also Published As

Publication number Publication date
ES2766573T3 (es) 2020-06-12
PE20121032A1 (es) 2012-08-25
NO2021013I1 (no) 2021-03-23
CN102482273A (zh) 2012-05-30
SI2445911T1 (sl) 2017-07-31
HK1167403A1 (en) 2012-11-30
KR101696669B1 (ko) 2017-01-16
NL301096I1 (pt) 2021-03-24
US8563545B2 (en) 2013-10-22
NL301096I2 (nl) 2021-04-12
KR101850716B1 (ko) 2018-04-20
LTPA2021504I1 (lt) 2021-04-12
DK2445911T3 (en) 2017-06-06
KR20120107919A (ko) 2012-10-04
EP3178819A1 (en) 2017-06-14
ME02699B (me) 2017-10-20
CY2021008I2 (el) 2021-06-25
FR21C1011I2 (fr) 2022-03-25
LTC2445911I2 (lt) 2022-09-26
NI201100222A (es) 2012-07-27
US20140100220A1 (en) 2014-04-10
EA201270075A1 (ru) 2012-12-28
BRPI1015569B1 (pt) 2020-10-27
US12042498B2 (en) 2024-07-23
CY1122649T1 (el) 2021-03-12
US9707237B2 (en) 2017-07-18
HRP20200033T1 (hr) 2020-03-20
JP2012530766A (ja) 2012-12-06
CN102482273B (zh) 2014-09-17
FR21C1011I1 (pt) 2021-05-07
CL2011003247A1 (es) 2012-04-13
MX344951B (es) 2017-01-12
DK3178819T3 (en) 2020-01-27
SI3178819T1 (sl) 2020-02-28
US10328081B2 (en) 2019-06-25
HRP20170826T1 (hr) 2017-08-25
US20210369727A1 (en) 2021-12-02
US9309244B2 (en) 2016-04-12
SG177363A1 (en) 2012-02-28
TWI462920B (zh) 2014-12-01
US20100331319A1 (en) 2010-12-30
US20160296530A1 (en) 2016-10-13
US20240325405A1 (en) 2024-10-03
CO6491040A2 (es) 2012-07-31
CY1119214T1 (el) 2018-02-14
CN104262337A (zh) 2015-01-07
AR077220A1 (es) 2011-08-10
US8999979B2 (en) 2015-04-07
RS56035B1 (sr) 2017-09-29
AU2017204744A1 (en) 2017-07-27
GB201200457D0 (en) 2012-02-22
PT2445911T (pt) 2017-06-12
KR101916194B1 (ko) 2018-11-07
CY2021008I1 (el) 2021-05-05
MA33448B1 (fr) 2012-07-03
US20180000831A1 (en) 2018-01-04
LT2445911T (lt) 2017-06-12
DOP2011000388A (es) 2012-04-15
UA107935C2 (xx) 2015-03-10
WO2010149769A1 (en) 2010-12-29
HUE033154T2 (en) 2017-11-28
ECSP12011626A (es) 2012-02-29
PL3178819T3 (pl) 2020-04-30
NZ596838A (en) 2014-01-31
KR20170007534A (ko) 2017-01-18
IL216667A (en) 2015-08-31
BRPI1015569B8 (pt) 2021-05-25
EP2445911B1 (en) 2017-03-01
AU2015218544A1 (en) 2015-09-17
LT3178819T (lt) 2020-01-27
US20200078365A1 (en) 2020-03-12
SMT201700265T1 (it) 2017-07-18
JP2014221825A (ja) 2014-11-27
CA2765985C (en) 2017-06-06
JP5591925B2 (ja) 2014-09-17
CR20120016A (es) 2012-02-09
EA021637B1 (ru) 2015-07-30
KR20180041262A (ko) 2018-04-23
ES2626908T3 (es) 2017-07-26
EP3178819B1 (en) 2019-12-04
AU2010264633B2 (en) 2015-06-04
US11000528B2 (en) 2021-05-11
AU2015218544B2 (en) 2017-04-27
SG10201703497YA (en) 2017-06-29
US8088764B2 (en) 2012-01-03
US20120142678A1 (en) 2012-06-07
GB2483424A (en) 2012-03-07
US20150274722A1 (en) 2015-10-01
ZA201109386B (en) 2012-08-29
TW201103936A (en) 2011-02-01
MX2011013450A (es) 2012-05-08
IL216667A0 (en) 2012-02-29
GB2483424B (en) 2012-07-18
CA2765985A1 (en) 2010-12-29
EP2445911A1 (en) 2012-05-02
HUS2100007I1 (hu) 2021-03-29
AU2010264633A1 (en) 2011-12-22
MY156664A (en) 2016-03-15
PL2445911T3 (pl) 2017-08-31
PT3178819T (pt) 2020-01-21
US12558360B2 (en) 2026-02-24
HUE047478T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1014956A2 (pt) agentes antinflamatórios.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0912412A2 (pt) compostos de pirazina fundidos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
BRPI0822292A2 (pt) Fármaco-alvo eficaz para o tratamento de tuberculose
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
BRPI0908602A2 (pt) método e composição farmacêutica para o tratamento de doenças autoimunes.
TH0901005406A (th) สารยับยั้งไพริดิลออกซีอินโดลของ vegf-r2 และการใช้งานของพวกมัน สำหรับการบำบัดโรค
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: ALFASIGMA S.P.A. (IT)